Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.58 |
| ▸ | HSD17B1 | P14061 | 7/20 | 0.54 |
| ▸ | HSD17B2 | P37059 | 7/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 2/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29744559 | 0.82 | ERN1 (0.64) | ERN1HSD17B1HSD17B2KCNH2HDAC1 | |
| SCHEMBL9335104 | 0.82 | KCNH2 (0.55) | ERN1CYP3A4KCNH2HDAC1HDAC2 | |
| SCHEMBL6068103 | 0.82 | ERN1 (0.64) | ERN1HSD17B1HSD17B2KCNH2HDAC1 | |
| SCHEMBL27813456 | 0.81 | PTGS1 (0.50) | ERN1CYP3A4KCNH2RPS6KB2 | |
| SCHEMBL17049365 | 0.81 | ERN1 (0.62) | ERN1KCNH2HDAC1HDAC2HDAC3 | |
| SCHEMBL7770514 | 0.79 | ERN1 (0.55) | ERN1KCNH2HDAC1HDAC2HDAC3 | |
| SCHEMBL1065997 | 0.78 | KCNH2 (0.70) | ERN1KCNH2HDAC1HDAC2HDAC3 | |
| SCHEMBL7056060 | 0.78 | ERN1 (0.58) | ERN1HSD17B1HSD17B2CYP3A4CYP2D6 | |
| SCHEMBL13494207 | 0.78 | KCNH2 (0.70) | CYP3A4KCNH2HDAC1HDAC2HDAC3 | |
| SCHEMBL4628631 | 0.77 | TNFRSF1A (0.60) | ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111032606-B | Bisphenol composition and method for producing same, and polycarbonate resin and method for producing same | 三菱化学株式会社 | 2024-01-30 | — | — | CN | disclosed |
| CN-112225681-B | Preparation method of 2, 4-di (n-octylthiomethylene) -6-methylphenol | 江苏极易新材料有限公司 | 2021-06-01 | — | — | CN | disclosed |
| CN-112225681-A | Preparation method of 2, 4-di (n-octylthiomethylene) -6-methylphenol | 江苏极易新材料有限公司 | 2021-01-15 | — | — | CN | disclosed |
| EP-2440517-B1 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2014-03-26 | — | — | EP | disclosed |
| US-8431610-B2 | Alkanoylamino benzamide aniline HDAC inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8263657-B2 | Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-8263657-B2 | Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-09-11 | — | — | US | disclosed |
| EP-1352650-B1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | INST MED MOLECULAR DESIGN INC (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-8097759-B2 | Inflammatory cytokine release inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097759-B2 | Inflammatory cytokine release inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-04-17 | — | — | US | disclosed |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-04-17 | — | — | US | disclosed |
| EP-1847263-A2 | Inhibitors against the production and release of inflammatory cytokines | Institute of Medicinal Molecular Design, Inc. (JP) | 2007-10-24 | — | — | EP | disclosed |
| EP-1844766-A2 | Inhibitors against the production and release of inflammatory cytokines | Institute of Medicinal Molecular Design, Inc. (JP) | 2007-10-17 | — | — | EP | disclosed |
| US-20070185059-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185059-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185110-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185110-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-02-22 | — | — | US | disclosed |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090779-A1 | ANTIALLERGIC AGENTS | NAT1, EPX, HRH2 | ERN1 2620/4885HSD17B1 231/4885HSD17B2 273/4885 |
| US-20070185110-A1 | Antiallergic agents | NAT1, EPX, AHR | ERN1 2842/4885HSD17B1 275/4885HSD17B2 324/4885 |
| US-20070185059-A1 | Antiallergic agents | NAT1, EPX, AHR | ERN1 2799/4885HSD17B1 233/4885HSD17B2 293/4885 |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | TYR, XDH, XPA | ERN1 4490/4885HSD17B1 714/4885HSD17B2 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.